A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C. Read more about A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C.
Lessons from LIMK1 enzymology and their impact on inhibitor design. Read more about Lessons from LIMK1 enzymology and their impact on inhibitor design.
A chemical probe of CARM1 alters epigenetic plasticity against breast cancer cell invasion. Read more about A chemical probe of CARM1 alters epigenetic plasticity against breast cancer cell invasion.
Aspartate/asparagine-β-hydroxylase crystal structures reveal an unexpected epidermal growth factor-like domain substrate disulfide pattern. Read more about Aspartate/asparagine-β-hydroxylase crystal structures reveal an unexpected epidermal growth factor-like domain substrate disulfide pattern.
Discovery of small molecule antagonists of the USP5 zinc finger ubiquitin-binding domain. Read more about Discovery of small molecule antagonists of the USP5 zinc finger ubiquitin-binding domain.
Targeted protein degradation: expanding the toolbox. Read more about Targeted protein degradation: expanding the toolbox.
Design and analysis of the 4-anilino-quin(az)oline kinase inhibition profiles of GAK/SLK/STK10 using quantitative structure activity relationships. Read more about Design and analysis of the 4-anilino-quin(az)oline kinase inhibition profiles of GAK/SLK/STK10 using quantitative structure activity relationships.
Multiple direct interactions of TBP with the MYC oncoprotein. Read more about Multiple direct interactions of TBP with the MYC oncoprotein.
Towards the Development of an In vivo Chemical Probe for Cyclin G Associated Kinase (GAK). Read more about Towards the Development of an In vivo Chemical Probe for Cyclin G Associated Kinase (GAK).
A fast iterative synthetic approach towards the identification of novel highly selective p38 MAP kinase inhibitors. Read more about A fast iterative synthetic approach towards the identification of novel highly selective p38 MAP kinase inhibitors.
